MedPath

Randomized controlled study comparing the Taperloc complete versus the Taperloc complete Microplasty.

Completed
Conditions
hip artrosis
hip wear
10023213
Registration Number
NL-OMON46938
Lead Sponsor
Zimmer Biomet Nederland BV
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

These are standard indications for usage of the Taperloc Complete and Taperloc Microplasty stem. ;Subjects with one of the following indications:
Non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and rheumatoid arthritis.
Correction of functional deformity. ;Additional inclusion criteria include:
Male or female
> 18 and * 70 years of age
Subjects willing to return for follow-up evaluations.
Subjects able to read and understand Dutch language.

Exclusion Criteria

Active Infection (or within 6 weeks after infection)
Sepsis
Osteomyelitis;Uncooperative patient or patient with neurologic disorders who are incapable of following directions
diagnosed Osteoporosis or Osteomalacia
Metabolic disorders which may impair bone formation
Distant foci of infections which may spread to the implant site
Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
Vascular insufficiency, muscular atrophy or neuromuscular disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary study endpoint is migration at two year measured with RSA</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary study parameters/endpoints are malalignment, incorrect sizing,<br /><br>subsidence and intraoperative fractures, early survival of the hip prosthesis<br /><br>at 2 year and Clinical performance based on the clinician based outcome (HHS<br /><br>and radiological evaluation) and the patient based outcomes (HOOS, EQ5D, Oxford<br /><br>Hip score, Forgotten Hip).<br /><br>One site will perform migration analysis with RSA. Migration at two year will<br /><br>be the primary endpoint for this sub-group.</p><br>
© Copyright 2025. All Rights Reserved by MedPath